Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for ABUS

Stock Name	Arbutus Biopharma Corp
Ticker	ABUS(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	CA03879J1003

Show aggregate ABUS holdings

News associated with ABUS

Wall Street Zen Downgrades Arbutus Biopharma (NASDAQ:ABUS) to Hold: Wall Street Zen cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a buy rating to a hold rating in a research note issued to investors on Friday morning. Separately, Chardan Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of Arbutus Biopharma in a report on Monday, August 11th. […] - 2025-09-08 02:54:58
Arbutus Biopharma Corp. Q2 Earnings Summary: (RTTNews) - Below are the earnings highlights for Arbutus Biopharma Corp. (ABUS): - 2025-08-06 08:49:24
10,000 Shares in Arbutus Biopharma Corporation (NASDAQ:ABUS) Bought by Cyndeo Wealth Partners LLC: Cyndeo Wealth Partners LLC bought a new position in Arbutus Biopharma Corporation (NASDAQ:ABUS – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $35,000. Other hedge funds and other institutional investors have also […] - 2025-06-18 05:50:55
Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Acquired by Wellington Management Group LLP: Wellington Management Group LLP grew its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 3.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 513,302 shares of the biopharmaceutical company’s stock after acquiring an additional 16,484 shares during the period. Wellington Management Group LLP’s holdings in Arbutus Biopharma were worth $1,678,000 […] - 2025-06-06 05:38:53
Millennium Management LLC Grows Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS): Millennium Management LLC boosted its position in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 36.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 343,028 shares of the biopharmaceutical company’s stock after buying an additional 92,068 shares during the quarter. Millennium Management LLC’s […] - 2025-06-05 04:24:59
ProShare Advisors LLC Grows Position in Arbutus Biopharma Co. (NASDAQ:ABUS): ProShare Advisors LLC increased its position in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 29.3% in the fourth quarter, HoldingsChannel reports. The firm owned 50,121 shares of the biopharmaceutical company’s stock after purchasing an additional 11,359 shares during the quarter. ProShare Advisors LLC’s holdings in Arbutus Biopharma were worth $164,000 as of its most […] - 2025-06-02 05:03:00
Deutsche Bank AG Increases Stake in Arbutus Biopharma Co. (NASDAQ:ABUS): Deutsche Bank AG increased its stake in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 77.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 171,766 shares of the biopharmaceutical company’s stock after acquiring an additional 75,212 shares during the quarter. Deutsche Bank AG’s holdings in Arbutus Biopharma were worth $562,000 at the end of […] - 2025-05-29 04:44:55
Northern Trust Corp Has $4.35 Million Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS): Northern Trust Corp increased its stake in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 8.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,330,683 shares of the biopharmaceutical company’s stock after acquiring an additional 102,241 shares during the period. Northern Trust Corp’s holdings in Arbutus Biopharma were worth $4,351,000 at the end of […] - 2025-05-22 04:22:55
Invesco Ltd. Purchases 3,780 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS): Invesco Ltd. grew its position in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 5.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 69,831 shares of the biopharmaceutical company’s stock after buying an additional 3,780 shares during the period. Invesco Ltd.’s holdings in Arbutus Biopharma […] - 2025-05-05 04:26:47
XTX Topco Ltd Acquires 22,568 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS): XTX Topco Ltd raised its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 75.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 52,581 shares of the biopharmaceutical company’s stock after purchasing an additional 22,568 shares during the quarter. XTX Topco Ltd’s holdings in Arbutus Biopharma were worth $172,000 at the […] - 2025-04-29 05:24:53
Rockefeller Capital Management L.P. Has $349,000 Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS): Rockefeller Capital Management L.P. boosted its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 69.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 106,615 shares of the biopharmaceutical company’s stock after acquiring an additional 43,615 […] - 2025-04-24 06:00:57
Arbutus Biopharma Announces Acceptance of Five Abstracts for Presentation at EASL Congress 2025: Arbutus Biopharma announces five abstracts accepted for EASL Congress 2025, focusing on hepatitis B therapies and clinical trials. - 2025-04-23 03:10:26
Bank of Montreal Can Purchases 15,567 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS): Bank of Montreal Can grew its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 3.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 455,880 shares of the biopharmaceutical company’s stock after purchasing an additional 15,567 shares during the quarter. Bank of Montreal Can’s holdings in Arbutus Biopharma were worth $1,491,000 as of […] - 2025-04-18 05:06:53
25,600 Shares in Arbutus Biopharma Co. (NASDAQ:ABUS) Acquired by KLP Kapitalforvaltning AS: KLP Kapitalforvaltning AS acquired a new stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,600 shares of the biopharmaceutical company’s stock, valued at approximately $84,000. A number of […] - 2025-04-11 04:49:00
Mitsubishi UFJ Asset Management Co. Ltd. Decreases Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS): Mitsubishi UFJ Asset Management Co. Ltd. lessened its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 15.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 69,660 shares of the biopharmaceutical company’s stock after selling 12,287 shares during the period. […] - 2025-04-04 05:12:59
Intech Investment Management LLC Has $187,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS): Intech Investment Management LLC increased its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 54.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 57,084 shares of the biopharmaceutical company’s stock after buying an additional 20,232 shares during the quarter. […] - 2025-03-28 07:12:50
Cibc World Markets Corp Takes $45,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS): Cibc World Markets Corp bought a new position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 13,672 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Other institutional investors and hedge funds […] - 2025-03-28 06:18:44
Arbutus Biopharma Co. (NASDAQ:ABUS) Sees Large Growth in Short Interest: Arbutus Biopharma Co. (NASDAQ:ABUS – Get Free Report) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 8,410,000 shares, a growth of 16.6% from the February 13th total of 7,210,000 shares. Approximately 4.6% of the shares of the stock are […] - 2025-03-21 04:26:50
Arbutus Biopharma (NASDAQ:ABUS) Downgraded to “Sell” Rating by StockNews.com: StockNews.com cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a hold rating to a sell rating in a research report released on Thursday morning. A number of other equities research analysts also recently commented on ABUS. Chardan Capital reissued a “buy” rating and issued a $5.00 price objective (up from $4.50) on shares […] - 2025-03-14 06:26:49
Comparing Arbutus Biopharma (NASDAQ:ABUS) & Akari Therapeutics (NASDAQ:AKTX): Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) and Akari Therapeutics (NASDAQ:AKTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership. Risk and Volatility Arbutus Biopharma has a […] - 2025-03-12 04:56:53
Arbutus Biopharma (NASDAQ:ABUS) Upgraded by StockNews.com to “Hold” Rating: Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday. Other equities analysts have also issued reports about the company. JMP Securities boosted their price target on Arbutus Biopharma to $5.00 and gave the company a […] - 2025-03-07 04:10:47
Arbutus Biopharma (NASDAQ:ABUS) Cut to “Sell” at StockNews.com: Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Tuesday. Other equities research analysts have also issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of […] - 2025-02-27 04:15:04
China Universal Asset Management Co. Ltd. Buys 3,870 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS): China Universal Asset Management Co. Ltd. grew its stake in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 40,179 shares of the biopharmaceutical company’s stock after acquiring an additional 3,870 […] - 2025-02-04 06:53:07

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) ABUS holdings

Date	Number of ABUS Shares Held	Base Market Value of ABUS Shares	Local Market Value of ABUS Shares	Change in ABUS Shares Held	Change in ABUS Base Value	Current Price per ABUS Share Held	Previous Price per ABUS Share Held
2025-12-24 (Wednesday)	127,932	USD 612,794	USD 612,794	0	USD 14,072	USD 4.79	USD 4.68
2025-12-23 (Tuesday)	127,932	USD 598,722	USD 598,722	-3,636	USD -22,279	USD 4.68	USD 4.72
2025-12-22 (Monday)	131,568	USD 621,001	USD 621,001	0	USD 38,155	USD 4.72	USD 4.43
2025-12-19 (Friday)	131,568	USD 582,846	USD 582,846	-10,180	USD -60,690	USD 4.43	USD 4.54
2025-12-18 (Thursday)	141,748	USD 643,536	USD 643,536	0	USD -14,175	USD 4.54	USD 4.64
2025-12-17 (Wednesday)	141,748	USD 657,711	USD 657,711	-1,645	USD -463	USD 4.64	USD 4.59
2025-12-16 (Tuesday)	143,393	USD 658,174	USD 658,174	-328	USD -53,245	USD 4.59	USD 4.95
2025-12-15 (Monday)	143,721	USD 711,419	USD 711,419	658	USD 37,592	USD 4.95	USD 4.71
2025-12-12 (Friday)	143,063	USD 673,827	USD 673,827	0	USD 5,723	USD 4.71	USD 4.67
2025-12-11 (Thursday)	143,063	USD 668,104	USD 668,104	674	USD 14,538	USD 4.67	USD 4.59
2025-12-10 (Wednesday)	142,389	USD 653,566	USD 653,566	0	USD 18,511	USD 4.59	USD 4.46
2025-12-09 (Tuesday)	142,389	USD 635,055	USD 635,055	0	USD -8,543	USD 4.46	USD 4.52

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ABUS by Blackrock for IE00BDZVHG35

Show aggregate share trades of ABUS

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-23 SELL -3,636 4.800 4.640 4.656 USD -16,929 3.70 Loss of -3,488 on sale
2025-12-19 SELL -10,180 4.620 4.420 4.440 USD -45,199 3.69 Loss of -7,650 on sale
2025-12-17 SELL -1,645 4.690 4.535 4.550 USD -7,486 3.68 Loss of -1,432 on sale
2025-12-16 SELL -328 5.035 4.570 4.617 USD -1,514 3.68 Loss of -309 on sale
2025-12-15 BUY 658 5.070 4.720 4.755 USD 3,129 3.67
2025-12-11 BUY 674 4.790 4.565 4.588 USD 3,092 3.66
2025-12-04 BUY 6,520 4.465 4.310 4.325 USD 28,202 3.64
2025-12-02 BUY 4,920 4.255 4.085 4.102 USD 20,182 3.63
2025-11-28 BUY 328 4.455 4.365 4.374 USD 1,435 3.63
2025-11-26 BUY 984 4.435 4.250 4.268 USD 4,200 3.62
2025-11-26 BUY 984 4.435 4.250 4.268 USD 4,200 3.62
2025-11-25 BUY 1,640 4.320 4.230 4.239 USD 6,952 3.62
2025-11-24 BUY 328 4.420 4.185 4.208 USD 1,380 3.61
2025-11-20 SELL -1,304 4.350 4.080 4.107 USD -5,356 3.61 Loss of -654 on sale
2025-11-19 BUY 325 4.460 4.260 4.280 USD 1,391 3.60
2025-11-18 BUY 1,950 4.520 4.335 4.354 USD 8,489 3.60
2025-11-17 BUY 652 4.680 4.470 4.491 USD 2,928 3.59
2025-11-14 BUY 325 4.690 4.460 4.483 USD 1,457 3.59
2025-11-12 BUY 325 4.870 4.630 4.654 USD 1,513 3.58
2025-11-10 BUY 324 4.625 4.503 4.515 USD 1,463 3.56
2025-11-06 BUY 324 4.600 4.350 4.375 USD 1,417 3.55
2025-11-04 BUY 325 4.578 4.450 4.463 USD 1,450 3.54
2025-10-30 BUY 1,630 4.945 4.540 4.580 USD 7,466 3.52
2025-10-29 BUY 652 4.610 4.760 4.745 USD 3,094 3.52
2025-10-22 SELL -1,296 4.430 4.510 4.502 USD -5,835 3.49 Loss of -1,310 on sale
2025-10-20 BUY 648 4.550 4.600 4.595 USD 2,978 3.48
2025-10-17 BUY 1,618 4.410 4.580 4.563 USD 7,383 3.47
2025-10-15 BUY 2,576 4.470 4.480 4.479 USD 11,538 3.47
2025-10-03 BUY 2,282 4.380 4.530 4.515 USD 10,303 3.46
2025-10-02 BUY 326 4.490 4.600 4.589 USD 1,496 3.45
2025-09-30 BUY 652 4.540 4.550 4.549 USD 2,966 3.44
2025-09-26 BUY 652 4.410 4.430 4.428 USD 2,887 3.43
2025-09-25 BUY 652 4.320 4.460 4.446 USD 2,899 3.42
2025-09-18 BUY 328 4.420 4.500 4.492 USD 1,473 3.41
2025-09-17 BUY 987 4.430 4.540 4.529 USD 4,470 3.41
2025-07-17 SELL -650 3.140 3.200 3.194 USD -2,076 3.41 Profit of 138 on sale
2025-07-11 SELL -2,616 3.170 3.260 3.251 USD -8,505 3.41 Profit of 423 on sale
2025-07-02 BUY 17,985 3.190 3.280 3.271 USD 58,829 3.42
2025-06-25 BUY 650 3.340 3.400 3.394 USD 2,206 3.42
2025-06-11 BUY 658 3.500 3.600 3.590 USD 2,362 3.42
2025-06-10 BUY 658 3.550 3.620 3.613 USD 2,377 3.42
2025-06-04 SELL -329 3.410 3.480 3.473 USD -1,143 3.42 Loss of -18 on sale
2025-04-23 BUY 327 3.240 3.320 3.312 USD 1,083 3.45
2025-04-10 SELL -2,616 3.120 3.140 3.138 USD -8,209 3.48 Profit of 884 on sale
2025-04-08 SELL -327 2.880 3.190 3.159 USD -1,033 3.49 Profit of 107 on sale
2025-04-07 SELL -326 3.010 3.140 3.127 USD -1,019 3.49 Profit of 119 on sale
2025-04-04 SELL -1,640 3.230 3.460 3.437 USD -5,637 3.49 Profit of 95 on sale
2025-04-01 BUY 1,344 3.480 3.600 3.588 USD 4,822 3.49
2025-03-31 SELL -990 3.490 3.540 3.535 USD -3,500 3.49 Loss of -40 on sale
2025-03-21 BUY 7,312 3.280 3.340 3.334 USD 24,378 3.51
2025-03-14 SELL -4,960 3.300 3.410 3.399 USD -16,859 3.52 Profit of 607 on sale
2025-03-07 SELL -616 3.310 3.420 3.409 USD -2,100 3.55 Profit of 84 on sale
2025-03-04 SELL -308 3.390 3.570 3.552 USD -1,094 3.55 Profit of 0 on sale
2025-02-25 BUY 618 3.450 3.700 3.675 USD 2,271 3.56
2025-02-19 SELL -306 3.390 3.420 3.417 USD -1,046 3.58 Profit of 49 on sale
2025-02-13 BUY 915 3.300 3.360 3.354 USD 3,069 3.60
2025-02-12 BUY 305 3.310 3.320 3.319 USD 1,012 3.60
2025-02-11 BUY 1,220 3.310 3.340 3.337 USD 4,071 3.61
2024-12-30 SELL -9,963 3.200 3.250 3.245 USD -32,330 3.72 Profit of 4,773 on sale
2024-11-18 SELL -4,938 3.520 3.680 3.664 USD -18,093 3.93 Profit of 1,315 on sale
2024-11-08 SELL -329 3.750 3.790 3.786 USD -1,246 3.96 Profit of 59 on sale
2024-10-21 SELL -332 4.070 4.150 4.142 USD -1,375 0.00 Loss of -1,375 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-23	SELL	-3,636	4.800	4.640	4.656	USD -16,929	3.70 Loss of -3,488 on sale
2025-12-19	SELL	-10,180	4.620	4.420	4.440	USD -45,199	3.69 Loss of -7,650 on sale
2025-12-17	SELL	-1,645	4.690	4.535	4.550	USD -7,486	3.68 Loss of -1,432 on sale
2025-12-16	SELL	-328	5.035	4.570	4.617	USD -1,514	3.68 Loss of -309 on sale
2025-12-15	BUY	658	5.070	4.720	4.755	USD 3,129	3.67
2025-12-11	BUY	674	4.790	4.565	4.588	USD 3,092	3.66
2025-12-04	BUY	6,520	4.465	4.310	4.325	USD 28,202	3.64
2025-12-02	BUY	4,920	4.255	4.085	4.102	USD 20,182	3.63
2025-11-28	BUY	328	4.455	4.365	4.374	USD 1,435	3.63
2025-11-26	BUY	984	4.435	4.250	4.268	USD 4,200	3.62
2025-11-26	BUY	984	4.435	4.250	4.268	USD 4,200	3.62
2025-11-25	BUY	1,640	4.320	4.230	4.239	USD 6,952	3.62
2025-11-24	BUY	328	4.420	4.185	4.208	USD 1,380	3.61
2025-11-20	SELL	-1,304	4.350	4.080	4.107	USD -5,356	3.61 Loss of -654 on sale
2025-11-19	BUY	325	4.460	4.260	4.280	USD 1,391	3.60
2025-11-18	BUY	1,950	4.520	4.335	4.354	USD 8,489	3.60
2025-11-17	BUY	652	4.680	4.470	4.491	USD 2,928	3.59
2025-11-14	BUY	325	4.690	4.460	4.483	USD 1,457	3.59
2025-11-12	BUY	325	4.870	4.630	4.654	USD 1,513	3.58
2025-11-10	BUY	324	4.625	4.503	4.515	USD 1,463	3.56
2025-11-06	BUY	324	4.600	4.350	4.375	USD 1,417	3.55
2025-11-04	BUY	325	4.578	4.450	4.463	USD 1,450	3.54
2025-10-30	BUY	1,630	4.945	4.540	4.580	USD 7,466	3.52
2025-10-29	BUY	652	4.610	4.760	4.745	USD 3,094	3.52
2025-10-22	SELL	-1,296	4.430	4.510	4.502	USD -5,835	3.49 Loss of -1,310 on sale
2025-10-20	BUY	648	4.550	4.600	4.595	USD 2,978	3.48
2025-10-17	BUY	1,618	4.410	4.580	4.563	USD 7,383	3.47
2025-10-15	BUY	2,576	4.470	4.480	4.479	USD 11,538	3.47
2025-10-03	BUY	2,282	4.380	4.530	4.515	USD 10,303	3.46
2025-10-02	BUY	326	4.490	4.600	4.589	USD 1,496	3.45
2025-09-30	BUY	652	4.540	4.550	4.549	USD 2,966	3.44
2025-09-26	BUY	652	4.410	4.430	4.428	USD 2,887	3.43
2025-09-25	BUY	652	4.320	4.460	4.446	USD 2,899	3.42
2025-09-18	BUY	328	4.420	4.500	4.492	USD 1,473	3.41
2025-09-17	BUY	987	4.430	4.540	4.529	USD 4,470	3.41
2025-07-17	SELL	-650	3.140	3.200	3.194	USD -2,076	3.41 Profit of 138 on sale
2025-07-11	SELL	-2,616	3.170	3.260	3.251	USD -8,505	3.41 Profit of 423 on sale
2025-07-02	BUY	17,985	3.190	3.280	3.271	USD 58,829	3.42
2025-06-25	BUY	650	3.340	3.400	3.394	USD 2,206	3.42
2025-06-11	BUY	658	3.500	3.600	3.590	USD 2,362	3.42
2025-06-10	BUY	658	3.550	3.620	3.613	USD 2,377	3.42
2025-06-04	SELL	-329	3.410	3.480	3.473	USD -1,143	3.42 Loss of -18 on sale
2025-04-23	BUY	327	3.240	3.320	3.312	USD 1,083	3.45
2025-04-10	SELL	-2,616	3.120	3.140	3.138	USD -8,209	3.48 Profit of 884 on sale
2025-04-08	SELL	-327	2.880	3.190	3.159	USD -1,033	3.49 Profit of 107 on sale
2025-04-07	SELL	-326	3.010	3.140	3.127	USD -1,019	3.49 Profit of 119 on sale
2025-04-04	SELL	-1,640	3.230	3.460	3.437	USD -5,637	3.49 Profit of 95 on sale
2025-04-01	BUY	1,344	3.480	3.600	3.588	USD 4,822	3.49
2025-03-31	SELL	-990	3.490	3.540	3.535	USD -3,500	3.49 Loss of -40 on sale
2025-03-21	BUY	7,312	3.280	3.340	3.334	USD 24,378	3.51
2025-03-14	SELL	-4,960	3.300	3.410	3.399	USD -16,859	3.52 Profit of 607 on sale
2025-03-07	SELL	-616	3.310	3.420	3.409	USD -2,100	3.55 Profit of 84 on sale
2025-03-04	SELL	-308	3.390	3.570	3.552	USD -1,094	3.55 Profit of 0 on sale
2025-02-25	BUY	618	3.450	3.700	3.675	USD 2,271	3.56
2025-02-19	SELL	-306	3.390	3.420	3.417	USD -1,046	3.58 Profit of 49 on sale
2025-02-13	BUY	915	3.300	3.360	3.354	USD 3,069	3.60
2025-02-12	BUY	305	3.310	3.320	3.319	USD 1,012	3.60
2025-02-11	BUY	1,220	3.310	3.340	3.337	USD 4,071	3.61
2024-12-30	SELL	-9,963	3.200	3.250	3.245	USD -32,330	3.72 Profit of 4,773 on sale
2024-11-18	SELL	-4,938	3.520	3.680	3.664	USD -18,093	3.93 Profit of 1,315 on sale
2024-11-08	SELL	-329	3.750	3.790	3.786	USD -1,246	3.96 Profit of 59 on sale
2024-10-21	SELL	-332	4.070	4.150	4.142	USD -1,375	0.00 Loss of -1,375 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ABUS

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE